Clinical trials: Mast Cell Disorder
Aggressive Systemic Mastocytosis, Mast Cell Leukemia
Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis
This phase 2 trial studies ibrutinib to see how well it works in treating patients with systemic (affecting the entire body) mastocytosis that has spread to other parts of the body and usually cannot be cured or controlled with…
- Conditions
- Aggressive Systemic Mastocytosis, Mast Cell Leukemia, Systemic Mastocytosis
- Trial name
- NCT02415608
- Testing
- Ibrutinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Jason Robert Gotlib
Mastocytosis, Cutaneous
Assessment of Burden Disease in Patients With Mast Cell Disorders
The symptoms caused by mast cell disorders can have a significant impact on the state of health of individuals, constituting a real burden for them, and consequently altering their quality of life.
- Trial name
- MCD&BuDi (NCT04615663)
- Testing
- Score SMI
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Toulouse
Leukemia, Systemic Mastocytosis
Obatoclax for Systemic Mastocytosis
The goal of this clinical research study is to learn if obatoclax mesylate can help to control systemic mastocytosis. The safety of this drug will also be tested.
- Trial name
- NCT00918931
- Testing
- Obatoclax Mesylate
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Life Threatening Diseases
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Exploratory study to examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate -sensitive tyrosine kinases, and to identify the contribution of…
- Trial name
- NCT00154388
- Testing
- Imatinib mesylate
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Indolent Systemic Mastocytosis
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment
The purpose of this study is to evaluate the efficacy and safety of oral masitinib versus placebo in the treatment of patients suffering from smouldering or indolent systemic mastocytosis with severe symptoms of mast cell…
- Trial name
- NCT04333108
- Testing
- Masitinib, Best Supportive Care
- Where
- 17 sites in France, Germany and 6 more
- Volunteers
- 140 people
- Sponsor
- AB Science
Mast Cell Activation Disease, Mast Cell Activation Syndrome
Ocular and Palpebral Manifestations of Mastocytosis (MOOMA)
Mastocytosis is a rare condition characterized by an accumulation of mast cell cells in one or more organs such as the liver, bone marrow, spleen and intestines. Its prevalence in the general population is 1 in 10,000.
- Conditions
- Mast Cell Activation Disease, Mast Cell Activation Syndrome, Mast Cell Disease, Urticaria Pigmentosa
- Trial name
- NCT04978740
- Testing
- Ophthalmological examination
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Poitiers University Hospital
Psoriasis, Cutaneous T Cell Lymphoma
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
The molecular mechanisms of action of photo(chemo)therapy in skin diseases are investigated in this study. The phototherapeutic modalities employed include UVB (ultraviolet B), UVA (ultraviolet A), PUVA (psoralen+UVA) and/or…
- Conditions
- Psoriasis, Cutaneous T Cell Lymphoma, Lymphoproliferative Disorders, Eczema
- Trial name
- BioUV2017 (NCT03340155)
- Testing
- Photo(chemo)therapy
- Where
- Austria
- Volunteers
- 240 people
- Sponsor
- Medical University of Graz
Inflammation, Acute ST Segment Elevation Myocardial Infarction
A Cohort Study of Correlation Between Mast Cells and Prognosis in Patients With Acute Myocardial Infarction
By including patients with acute myocardial infarction, mast cell markers were analyzed and the relationship between mast cells and patients with acute myocardial infarction was analyzed
- Conditions
- Inflammation, Acute ST Segment Elevation Myocardial Infarction, Prognosis
- Trial name
- NCT05802667
- Testing
- Tryptase
- Volunteers
- 300 people
- Sponsor
- Peking University Third Hospital
Cutaneous Mastocytosis, Systemic Mastocytosis
Mastocytosis From Pediatric Age to Adulthood: Local Registry of Cutaneous and Systemic Mastocytosis
Given the renewed focus on mastocytosis (recognized in Italy as a rare disease since 2018) and emerging clinical and immunogenetic knowledge, and considering the rarity of the disease and limited understanding of its progression…
- Trial name
- MaRe (NCT07142473)
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Osteoporosis, Systemic Mastocytosis
Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis
The study is looking at the efficacy of subcutaneously administrated denosumab 60 mg every 6 months versus placebo after 3 years, by analyze of lumbar spine bone mineral density (BMD) in systemic mastocytosis.
- Trial name
- DenosuMast (NCT03401060)
- Testing
- Denosumab
- Where
- 11 sites in France
- Volunteers
- 24 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Biphenotypic Leukemia, Acute Leukemia
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
This phase II trial studies how well naive T-cell depletion works in preventing chronic graft-versus-host disease in children and young adults with blood cancers undergoing donor stem cell transplant.
- Conditions
- Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia
- Trial name
- NCT03779854
- Testing
- Total-Body Irradiation, Thiotepa, Fludarabine
- Where
- 9 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Asthma, Mastocytosis
Mast Cell Activation Test in Allergic Disease
Activation of mast cells in the immune system is known to cause allergic reactions sometimes with severe systemic symptoms. The investigators have recently developed a blood-based mast cell activation diagnostic test in which…
- Conditions
- Asthma, Mastocytosis, Mast Cell Activation Syndrome, Food Allergy
- Trial name
- NCT03406325
- Where
- Hong Kong
- Volunteers
- 19 people
- Sponsor
- Hong Kong Sanatorium & Hospital
Primary Myelofibrosis, Polycythemia Vera
Myeloproliferative Neoplasms (MPNs) Patient Registry
The mandate of this MPN registry is to collect clinical information, including molecular results, from consenting patients with a variety of MPNs at different time points during the course of their disease.
- Conditions
- Primary Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia, Mastocytosis
- Trial name
- NCT02760238
- Testing
- Observational
- Where
- Canada
- Volunteers
- 5,000 people
- Sponsor
- University Health Network, Toronto
Mastocytosis, Systemic
Quality of Life and Disease-related Symptoms in Individuals With Systemic Mastocytosis
Systemic Mastocytosis is a rare and complex disease caused by accumulation of mast cells. The skin, bones, gastrointestinal tract, bone marrow and liver are the organs most often affected.
- Trial name
- NCT06065007
- Testing
- No intervention
- Where
- 2 sites in Sweden
- Volunteers
- 400 people
- Sponsor
- Uppsala University
Alzheimer Disease
Masitinib in Patients With Mild Alzheimer's Disease
Masitinib is an orally administered tyrosine kinase inhibitor that targets activated cells of the neuroimmune system (mast cells and microglia).
- Trial name
- NCT05564169
- Testing
- Masitinib (4.5), Standard of care
- Where
- 9 sites in France, Spain
- Volunteers
- 600 people
- Sponsor
- AB Science
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer
This clinical trial studies massage therapy given by caregiver in treating quality of life of young patients undergoing treatment for cancer.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
- Trial name
- NCT01053494
- Testing
- massage therapy, questionnaire administration, quality-of-life assessment
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Wake Forest University Health Sciences
Obesity
Gastric Mucosal Mast Cells, Macrophages and Microvessels in Obesity
This comparative cross-sectional study compared tryptase-positive mast cells, CD68-positive macrophages, and CD31-positive microvessels in the gastric mucosa of 31 patients with obesity undergoing sleeve gastrectomy and 33…
- Trial name
- NCT07448896
- Testing
- Sleeve gastrectomy, Diagnostic upper gastrointestinal endoscopy with biopsy
- Where
- Egypt
- Volunteers
- 64 people
- Sponsor
- General Committee of Teaching Hospitals and Institutes, Egypt
Mastocytosis
Study on Mastocytosis for Rupatadine Treatment
Study title: An exploratory, randomised, double-blind, placebo controlled crossover study to assess the efficacy of 20 mg Rupatadine on the treatment of mastocytosis symptoms.
- Trial name
- SMART (NCT01481909)
- Testing
- Rupatadin
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Marcus Maurer
Systemic Mastocytosis
Use of Tamoxifen in Systemic Mastocytosis
In this study, the investigators will determine the utility of Tamoxifen, a non-cytotoxic agent, to improve quality of life, biochemical parameters, and bone marrow involvement in systemic mastocytosis patients having 1) up to…
- Trial name
- NCT01334996
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Mayo Clinic
Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN)
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm…
- Conditions
- Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL), Aggressive Systemic Mastocytosis (ASM)
- Trial name
- NCT04996875
- Testing
- bezuclastinib
- Where
- 42 sites in United States, Australia and 12 more
- Volunteers
- 140 people
- Sponsor
- Cogent Biosciences, Inc.